CeriBell, Inc. Common Stock (CBLL) Stock
NASDAQ · CBLL
Key stats
- Market cap
- $1.05B
- Price / Earnings ratio
- -15.8x
- EPS (TTM)
- -$3.39
- Volume
- Loading
- 52-week high
- $28.11
- 52-week low
- $10.85
Source: third-party data provider, as of October 24, 2026
Compare with CBLL
Recent news

MarketBeat
CeriBell Expands EEG Platform Beyond Seizures With Delirium, Pediatric Push
CBLLAugust 12, 2026
MarketBeat
CeriBell Expands EEG Platform Beyond Seizures With Delirium, Pediatric Push
CBLL

Zacks Investment Research
Here's What Key Metrics Tell Us About CeriBell, Inc. (CBLL) Q2 Earnings
CBLLAugust 11, 2026
Zacks Investment Research
Here's What Key Metrics Tell Us About CeriBell, Inc. (CBLL) Q2 Earnings
CBLL

Zacks Investment Research
CeriBell, Inc. (CBLL) Reports Q2 Loss, Tops Revenue Estimates
CBLLAugust 10, 2026
Zacks Investment Research
CeriBell, Inc. (CBLL) Reports Q2 Loss, Tops Revenue Estimates
CBLL

MarketBeat
CeriBell Q2 Earnings Call Highlights
CBLLAugust 10, 2026
MarketBeat
CeriBell Q2 Earnings Call Highlights
CBLL
Technical indicators
- RSI 14
- 60.99
- MACD 12/26/9
- 0.89
- EMA 9 of MACD
- 0.64
- MACD histogram
- 0.24
- SMA 50
- $24.55
- Price above SMA 50
- EMA 50
- $24.13
- Price above EMA 50
- SMA 200
- $20.66
- Price above SMA 200
- EMA 200
- $21.06
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of October 22, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 3 analyst ratings
Strong Sell0
Sell0
Hold0
Buy3
Strong Buy0
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Revenue
Net income
Net margin %
2025
107M71M35M0
Debt & Balance Sheet
Total assets
Total liabilities
2025
235M155M78M0
Revenue to Profit
2025$89.1M
Revenue$0.0
Cost of revenue$78.3M
Gross profit$0.0
Operating expenses$-53.4M
Net incomeEarnings
No data available
Source: third-party data provider
Latest news

MarketBeat
CeriBell Expands EEG Platform Beyond Seizures With Delirium, Pediatric Push
CBLLAugust 12, 2026
MarketBeat
CeriBell Expands EEG Platform Beyond Seizures With Delirium, Pediatric Push
CBLL

Zacks Investment Research
Here's What Key Metrics Tell Us About CeriBell, Inc. (CBLL) Q2 Earnings
CBLLAugust 11, 2026
Zacks Investment Research
Here's What Key Metrics Tell Us About CeriBell, Inc. (CBLL) Q2 Earnings
CBLL

Zacks Investment Research
CeriBell, Inc. (CBLL) Reports Q2 Loss, Tops Revenue Estimates
CBLLAugust 10, 2026
Zacks Investment Research
CeriBell, Inc. (CBLL) Reports Q2 Loss, Tops Revenue Estimates
CBLL

MarketBeat
CeriBell Q2 Earnings Call Highlights
CBLLAugust 10, 2026
MarketBeat
CeriBell Q2 Earnings Call Highlights
CBLL

MarketBeat
CeriBell Sees ‘Early Innings' Growth as Hospital Accounts and Usage Hit Records
CBLLMay 15, 2026
MarketBeat
CeriBell Sees ‘Early Innings' Growth as Hospital Accounts and Usage Hit Records
CBLL

MarketBeat
CeriBell Q1 Earnings Call Highlights
CBLLMay 11, 2026
MarketBeat
CeriBell Q1 Earnings Call Highlights
CBLL

Zacks Investment Research
CeriBell, Inc. (CBLL) Reports Q1 Loss, Beats Revenue Estimates
CBLLMay 11, 2026
Zacks Investment Research
CeriBell, Inc. (CBLL) Reports Q1 Loss, Beats Revenue Estimates
CBLL

Zacks Investment Research
CeriBell, Inc. (CBLL) Reports Q4 Loss, Beats Revenue Estimates
CBLLFebruary 25, 2026
Zacks Investment Research
CeriBell, Inc. (CBLL) Reports Q4 Loss, Beats Revenue Estimates
CBLL

Zacks Investment Research
CBLL Wins FDA Breakthrough Status for AI-Based LVO Stroke Detection
CBLLJanuary 6, 2026
Zacks Investment Research
CBLL Wins FDA Breakthrough Status for AI-Based LVO Stroke Detection
CBLL

Zacks Investment Research
CBLL Gets FDA Consent for One-of-a-Kind Delirium Monitoring Solution
CBLLDecember 12, 2025
Zacks Investment Research
CBLL Gets FDA Consent for One-of-a-Kind Delirium Monitoring Solution
CBLL
About CeriBell, Inc. Common Stock
No description available.
SectorHealthcare
IndustryMedical Devices
Employees327
CEODr. Xingjuan Chao Ph.D.
IPO DateOct 11, 2024
HeadquartersSunnyvale, CA
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Xingjuan Chao Ph.D. | Co-Founder, President, CEO & Director | 1981 |
| Mr. Scott Blumberg | Chief Financial Officer | — |
| Dr. Josef Parvizi M.D., Ph.D. | Co-Founder, Chief Medical Advisor & Director | 1969 |
| Dr. Raymond Woo Ph.D. | Chief Technology Officer | 1983 |
| Ms. Louisa Daniels J.D., M.B.A. | General Counsel | 1958 |
| Mr. Brian P. Price | Senior Vice President of Marketing | — |
| Ms. Kim McKeon | VP of People & Culture | — |
| Ms. Baharan Kamousi Ph.D. | Senior Vice President of Data Science | — |
| Mr. Joseph Sean Manni | Chief Revenue Officer | 1974 |
| Mr. David Foehr | Senior Vice President of Finance | — |
Fundamentals
Valuation
Price-to-sales ratio15.92
Price-to-book value8.12
Profitability
Return on Equity-45.00%
Return on Assets-36.00%
Return on Sales-63.00%
Gross margin (latest quarter)92.32%
EBITDA$-63.09M
Trading
Average volume416,761
Source: third-party data provider, as of October 24, 2026
Technical indicators
- RSI 14
- 60.99
- MACD 12/26/9
- 0.89
- EMA 9 of MACD
- 0.64
- MACD histogram
- 0.24
- SMA 50
- $24.55
- Price above SMA 50
- EMA 50
- $24.13
- Price above EMA 50
- SMA 200
- $20.66
- Price above SMA 200
- EMA 200
- $21.06
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of October 22, 2026. Technical data, not a recommendation.
Analyst views
3 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Analyst consensus:Buy
100% Buy
0% Hold
0% Sell
Analyst price target
- Low
- $26.00
- Average
- $29.67
- High
- $33.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024 | +5.2 | +9.0 | -7.6 | |||||||||
| 2025 | -11.0 | +0.3 | -22.0 | -14.3 | +3.3 | +9.0 | -22.5 | -16.3 | +0.6 | -1.4 | +49.6 | +31.6 |
| 2026 | -3.2 | -7.7 | +0.9 | +9.0 | -10.0 | +10.4 | -11.5 | +31.0 | -0.8 | +16.1 |
Compare stocks
Market cap
$1.05B
-
-
-
Price / Earnings ratio
-15.80
-
-
-
Price / Sales ratio
15.92
-
-
-
Dividend yield
0.00%
-
-
-
Average volume
416,761
-
-
-
Earnings per share
$-3.39
-
-
-



